Coherus Oncology, Inc. (CHRS)
(Delayed Data from NSDQ)
$1.61 USD
+0.08 (5.23%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.61 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CHRS 1.61 +0.08(5.23%)
Will CHRS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CHRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHRS
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2
CHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Other News for CHRS
CHRS forms Golden Cross on September 19
Is CHRS set to rally? Expansion Breakout shows up after rocketing 13.33%
CHRS falls 0.74% on September 17, leaving the technical picture intact
CHRS's price rises by 7.09% on September 16, though its technical setup remains stable.
MACD Bearish Signal Line Cross appears for CHRS after 1.55% move